This report analyzes the venture capital (VC) investment activity in Q4 2025 in the Pharma sector.
Key Highlights
- In Q4 2025, the global pharma sector saw investments totaling $9.6 billion, marking an 70.6% increase from Q3 2025. Investment volume also rose, with 206 deals, representing a 30.4% uptick. Oncology emerged as the top therapy area with 89 deals backed by 325 investors.
Report Scope
- This report provides an overview of VC investment activity globally in Q4 2025 in the Pharma sector involving biopharmaceutical drug companies.
- It identifies key trends, and the most notable deals announced in Q4 2025 in the Pharma sector.
Reasons to Buy
- Companies that strategically invest in venture funding position themselves for success, while those that fail to adapt risk falling behind.
- This report provides an overview of global VC investment trends in the pharma sector from the past quarter, offering insights into the industry landscape and key market movements.
Table of Contents
1 Table of Contents1.1 List of Tables
1.2 List of Figures
2 Pharma VC Investment Analysis in Q4 2025
3 Global VC Investment Trends in Pharma
4 Global Quarterly VC Investment Trends in Pharma
5 Global VC Investment Trends for Biotechs
6 Top VC Investments in Pharma Q4 2025
7 Global Mega VC Investment Trends in Pharma
8 Global Quarterly Mega VC Investment Trends in Pharma
9 Global VC Investment in Pharma by Deal Size Analysis
10 Global Investment in Pharma by Funding Stage Analysis
11 Global VC Investment Trends in Pharma by Top Deal Stage
12 Regional VC Investment Comparison in Pharma - Q4 2025
13 Regional VC Investment in Pharma by Value and Volume
14 VC Investment Analysis in Pharma by Top 10 Countries
15 VC Investment Analysis in Pharma by Top 10 Therapy Areas
16 Top VC Investors in Pharma by Value in Q4 2025
17 Further Information
17.1 Methodology
18 Contact the Publisher
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Kailera Therapeutics
- Tubulis
- Kardigan
- Souffle Therapeutics
- Braveheart Bio
- Electra Therapeutics
- Expedition Therapeutics
- Hemab
- Veradermics
- Adcytherix
- TRIANA Biomedicines
- Ambros Therapeutics
- Aspen Neuroscience
- Atavistik Bio
- Iambic Therapeutics
- Syremis Therapeutics
